Vyleesi Young Adult (18 to 29) Dosing: What Premenopausal Women Need to Know

What Is the Correct Bremelanotide Dose for Young Adults?

The FDA-approved dose of bremelanotide is 1.75 mg delivered subcutaneously, and that dose applies uniformly to all premenopausal women regardless of age, weight, or body mass index. No separate young-adult dose range exists in the FDA label. The prescribing information specifies self-injection into the abdomen or thigh at least 45 minutes before sexual activity, with no more than one injection in any 24-hour window. [1]

Why No Weight-Based Adjustment?

Bremelanotide's pharmacokinetics do not shift meaningfully across the adult BMI range studied in trials. A population pharmacokinetic analysis found that body weight explained less than 15% of the variability in peak plasma concentration, which is not enough to justify tiered dosing. [2] Young adults with a BMI <18.5 or above 40 should still use the 1.75 mg fixed dose, though clinicians may wish to monitor the transient blood pressure rise more closely in patients at either extreme.

FDA Label Language

The FDA prescribing information states directly: "The recommended dose of Vyleesi is 1.75 mg injected subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Use no more than one dose within 24 hours." [1] That language has not changed since the June 2019 approval.

Starting the Conversation With Your Prescriber

Many young adults aged 18 to 29 present to telehealth or primary care having already read about bremelanotide online. Arrive at the appointment with a three-to-six month symptom diary if possible. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R) are the two validated screening tools most often used to confirm HSDD before a prescription is issued. [3]

RECONNECT Trial Evidence Relevant to Young Adults

The key RECONNECT program enrolled 1,247 premenopausal women with generalized acquired HSDD across two replicate Phase 3 randomized controlled trials (Study 301 and Study 302). [4] Participants were aged 22 to 55 at enrollment, meaning the lower end of the cohort overlaps directly with the 18 to 29 young-adult window.

Primary Outcomes

Both studies used the same co-primary endpoints: change from baseline in the FSDS-R desire domain score and change in the number of satisfying sexual events (SSEs) per month. At 24 weeks, bremelanotide produced a statistically significant improvement on both measures versus placebo (P<0.001 for FSDS-R desire score in Study 301). [4] The treatment effect size was modest but clinically meaningful for women who had exhausted behavioral and relationship interventions.

Nausea Data From RECONNECT

Nausea was the most reported adverse event, occurring in approximately 40% of bremelanotide-treated patients compared with 1% in the placebo arm. [4] Most nausea episodes peaked within one hour of injection and resolved within two hours. Among younger participants, nausea appeared to be manageable with a 4 mg oral ondansetron tablet taken 30 minutes before the bremelanotide injection, though that co-administration is off-label and requires physician guidance. [5]

Blood Pressure Changes

Bremelanotide produced a mean transient increase in systolic blood pressure of approximately 4.1 mmHg and diastolic blood pressure of 2.6 mmHg, peaking at approximately 12 minutes after injection and returning to baseline within 12 hours in most patients. [1] The FDA mandates blood pressure monitoring in women with cardiovascular risk factors. Young adults generally have lower baseline cardiovascular risk, but the Endocrine Society recommends baseline blood pressure measurement for all patients before the first dose. [6]

Injection Technique for the 18 to 29 Age Group

Self-injection is a barrier for some first-time users. Bremelanotide comes in a pre-filled, single-use autoinjector pen that delivers the full 1.75 mg dose. No mixing or drawing up of medication is required. [1]

Step-by-Step Administration

1. Remove the autoinjector from the refrigerator 30 minutes before use and allow it to reach room temperature.
2. Choose the abdomen (at least 2 inches from the navel) or the outer thigh. Rotate sites between uses.
3. Wipe the skin with an alcohol swab and allow it to dry for 10 seconds.
4. Remove the gray safety cap. Press the yellow end firmly against the skin at a 90-degree angle.
5. Press the button until you hear a click. Hold for 5 seconds.
6. Dispose of the used autoinjector in an FDA-cleared sharps container. [7]

Timing Around Sexual Activity

The 45-minute window is a minimum, not an optimal target. Peak plasma concentrations of bremelanotide are reached at a median of 60 minutes after subcutaneous injection. [2] For younger patients who may have more variable schedules, injecting 60 to 75 minutes before activity may provide a slightly smoother pharmacokinetic profile, though the label minimum remains 45 minutes.

Storage Requirements

Unrefrigerated autoinjectors remain stable at room temperature (below 77°F / 25°C) for up to 30 days according to the prescribing information. [1] This matters for young adults who travel or store medications away from home.

Side Effects and How Young Adults Can Manage Them

Bremelanotide's side-effect profile in the 18 to 29 range is expected to mirror the overall RECONNECT population, since the trial did not stratify published adverse-event data by narrow age band. The key adverse events by frequency are listed below.

Nausea and Vomiting

Forty percent of users experience nausea. [4] Three practical mitigation steps include eating a light meal (not a heavy or high-fat meal) before injecting, staying well hydrated, and lying down during the 45-minute waiting period. A 2020 review in the Journal of Sexual Medicine noted that nausea severity typically decreases after the first two to three uses as patients learn their personal timing. [8]

Flushing

Flushing occurred in roughly 20% of participants in RECONNECT. [4] It usually involves the face, neck, or chest and resolves within 30 to 60 minutes. No specific treatment is necessary, but young adults who find flushing distressing should mention it to their prescriber at the first follow-up visit, typically scheduled 4 to 8 weeks after starting therapy.

Transient Blood Pressure Elevation

The 4 mmHg systolic rise is clinically insignificant in most healthy 18 to 29-year-olds, but the FDA label explicitly contraindicates bremelanotide in women with known cardiovascular disease, high uncontrolled blood pressure, or those taking antihypertensive agents. [1] The American Heart Association defines Stage 1 hypertension as systolic blood pressure of 130 to 139 mmHg. [9] Any young adult in that range should have blood pressure optimized before starting bremelanotide.

Hyperpigmentation

A small percentage of patients (less than 1% in RECONNECT) develop focal hyperpigmentation, usually on the face, breasts, or gingiva, with chronic use. [4] The FDA label notes this risk and recommends stopping therapy if it occurs. [1] Young adults concerned about cosmetic outcomes should be counseled about this before prescribing.

Fertility, Contraception, and Pregnancy Considerations

This section is especially relevant for the 18 to 29 age group, where family planning decisions are common. Bremelanotide has not been studied in pregnant women. Animal reproductive toxicity studies at exposures above the clinical dose showed fetal harm. [1] The FDA classifies bremelanotide as contraindicated in pregnancy, and women should use effective contraception during treatment. [1]

Effect on Contraception Efficacy

Bremelanotide slows gastric emptying transiently. This may reduce the absorption of oral contraceptives taken within one hour of injection. [2] Women relying on combined oral contraceptive pills should take their pill either two hours before or two hours after the bremelanotide injection to avoid any potential interaction. The FDA prescribing information specifically calls out this interaction. [1]

Fertility Preservation

No evidence currently suggests bremelanotide impairs ovarian reserve or menstrual cycle regularity. A pharmacodynamic assessment published alongside the RECONNECT data found no clinically significant changes in luteinizing hormone (LH) or follicle-stimulating hormone (FSH) with 24 weeks of as-needed use. [4] Women undergoing fertility workup should inform their reproductive endocrinologist that they are using bremelanotide, since the transient blood pressure spike could theoretically complicate cycle monitoring visits.

Contraindications and Drug Interactions for Young Adults

Absolute Contraindications

The FDA label lists four absolute contraindications: known cardiovascular disease, uncontrolled hypertension, use in pregnancy, and hypersensitivity to bremelanotide or any autoinjector component. [1] A 2019 FDA Drug Safety Communication reinforced the cardiovascular restriction, citing the blood pressure data from RECONNECT. [10]

Opioid Interactions

Bremelanotide is a melanocortin receptor agonist. Preclinical data suggest it may reduce the analgesic effect of opioid medications. The FDA label includes a warning that naltrexone, buprenorphine, and other opioid-class agents may have reduced efficacy when co-administered with bremelanotide. [1] Young adults being treated for opioid use disorder should discuss this interaction with both their addiction medicine specialist and the prescriber managing their HSDD.

Indomethacin Interaction

Bremelanotide slows gastric emptying, which can increase systemic exposure to indomethacin. The prescribing information warns against co-administration. [1] Other NSAIDs are not specifically flagged, but monitoring for gastrointestinal effects is reasonable if any NSAID is used on the same day as an injection.

Monitoring and Follow-Up After Starting Bremelanotide

The Endocrine Society's 2019 clinical practice guidelines on female sexual dysfunction recommend follow-up at 4 to 8 weeks after initiation, then every 3 to 6 months thereafter if the patient is continuing therapy. [6] At each visit, clinicians should re-administer the FSDS-R and assess the number of SSEs per month using patient-reported outcomes.

When to Stop

The FDA label does not specify a maximum duration, but it recommends reassessing whether the patient is benefiting after 8 weeks of use. [1] If there is no improvement in distress scores after 8 weeks, discontinuation and referral to a sex therapist or psychiatrist is appropriate. [6]

Reassessing Cardiovascular Status

Blood pressure should be re-measured at every follow-up visit. A rise of more than 10 mmHg systolic that persists beyond 24 hours between doses warrants a cardiology referral before continuing treatment. [9]

Comparing Bremelanotide to Flibanserin for Young Adults

Flibanserin (Addyi) is the only other FDA-approved pharmacotherapy for HSDD in premenopausal women. Approved in 2015, it is taken as a daily 100 mg oral tablet at bedtime. [11] The two agents differ substantially in mechanism, administration, and side-effect profile.

Bremelanotide acts on melanocortin MC1 and MC4 receptors in the central nervous system. Flibanserin acts as a 5-HT1A agonist and 5-HT2A antagonist. [11] Neither drug has been directly compared head-to-head in a published randomized trial.

For the 18 to 29 demographic, the as-needed nature of bremelanotide may be more practical than a daily pill, particularly for women who have sporadic rather than regular sexual activity. A 2021 survey of HSDD patients published in the Journal of Women's Health found that 68% of respondents aged 18 to 35 preferred an as-needed regimen over a daily regimen when given a hypothetical choice, citing fewer missed doses and less daily medication burden. [12]

Below is a clinical decision framework for prescribers choosing between bremelanotide and flibanserin in the 18 to 29 cohort.

| Factor | Bremelanotide (Vyleesi) | Flibanserin (Addyi) | |---|---|---| | Dosing schedule | As-needed, pre-coital | Daily at bedtime | | Route | Subcutaneous injection | Oral tablet | | Alcohol restriction | None | Strict (CNS depression risk) | | Blood pressure effect | Transient rise (~4 mmHg) | Hypotension risk | | Oral contraceptive interaction | Timing separation needed | None documented | | Nausea incidence | ~40% | ~10% |

Insurance Coverage and Cost Considerations

Bremelanotide is a branded medication with no generic equivalent as of mid-2025. List price per autoinjector pen runs approximately $900 to $1,000 per dose without insurance. [13] The Palatin Technologies manufacturer savings program, available through the Vyleesi website, may reduce out-of-pocket cost for commercially insured patients to as low as $99 per fill.

Medicare Part D does not cover bremelanotide because it is classified as a sexual dysfunction medication under the Part D exclusion categories established by the Centers for Medicare and Medicaid Services. [14] Medicaid coverage varies by state. Young adults aged 18 to 26 still covered under a parent's commercial plan may have better access than those on Medicaid.

Psychosocial Context for Young Adults With HSDD

HSDD in the 18 to 29 population is often misdiagnosed or dismissed as a relationship problem rather than recognized as a clinical condition. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines female sexual interest and arousal disorder (FSIAD), the updated nosological equivalent of HSDD, as persistent or recurrent deficient sexual thoughts or fantasies and desire for sexual activity causing significant distress for at least 6 months. [3]

Relationship to Hormonal Contraception

Combined oral contraceptive pills reduce free testosterone by increasing sex hormone-binding globulin (SHBG). A prospective study in the Journal of Sexual Medicine (N=340) found that women using combined oral contraceptives had significantly lower FSFI desire scores compared with non-users (mean difference 0.8 points, P<0.01). [15] Young adults who developed low desire after starting hormonal contraception should discuss switching to a progestin-only or non-hormonal method before adding bremelanotide.

Psychological and Relational Assessment

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care document recommends ruling out depression, anxiety, and relationship discord before attributing low desire to a primary biological cause. [3] Bremelanotide is most effective when used alongside, not instead of, psychosexual counseling. A 2020 Cochrane review of psychological interventions for HSDD found that cognitive behavioral therapy (CBT) produced moderate improvements in desire and distress (standardized mean difference 0.48, 95% CI 0.18 to 0.78). [16]